← All trials
NCT06647810
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 13, 2024
- Primary completion
- Dec 12, 2024
- Completion date
- Dec 23, 2024
- First posted
- Oct 18, 2024
- Last posted
- Nov 25, 2024
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.